1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznań, Poland.
Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznań, Poland.
Int J Mol Sci. 2023 Mar 18;24(6):5817. doi: 10.3390/ijms24065817.
MicroRNAs (miRNAs) are currently investigated as crucial regulatory factors which may serve as a potential therapeutic target. Reports on the role of miRNA in patients with coronary artery aneurysmal disease (CAAD) are limited. The present analysis aims to confirm the differences in the expression of previously preselected miRNAs in larger study groups and evaluate their usefulness as potential markers of CAAD. The study cohort included 35 consecutive patients with CAAD (Group 1), and two groups of 35 patients matched Group 1 regarding sex and age from the overall cohort of 250 patients (Group 2 and Group 3). Group 2 included patients with angiographically documented coronary artery disease (CAD), while Group 3 enrolled patients with normal coronary arteries (NCA) assessed during coronary angiography. We applied the RT-qPCR method using the custom plates for the RT-qPCR array. We confirmed that the level of five preselected circulating miRNAs was different in patients with CAAD compared to Group 2 and Group 3. We found that miR-451a and miR-328 significantly improved the CAAD prediction. In conclusion, miR-451a is a significant marker of CAAD compared to patients with CAD. In turn, miR-328-3p is a significant marker of CAAD compared to patients with NCA.
微小 RNA（miRNA）目前被研究为关键的调节因子，可能作为一种潜在的治疗靶点。关于 miRNA 在冠状动脉瘤疾病（CAAD）患者中的作用的报告有限。本分析旨在在更大的研究组中确认先前预选 miRNA 的表达差异，并评估其作为 CAAD 潜在标志物的用途。研究队列包括 35 例连续的 CAAD 患者（第 1 组），以及从 250 例患者的总体队列中按性别和年龄与第 1 组匹配的两组 35 例患者（第 2 组和第 3 组）。第 2 组包括经血管造影证实的冠状动脉疾病（CAD）患者，而第 3 组则招募了在冠状动脉造影期间评估为正常冠状动脉（NCA）的患者。我们使用 RT-qPCR 阵列的定制板应用 RT-qPCR 方法。我们证实与第 2 组和第 3 组相比，CAAD 患者的五种预选循环 miRNA 的水平不同。我们发现 miR-451a 和 miR-328 显著改善了 CAAD 的预测。总之，与 CAD 患者相比，miR-451a 是 CAAD 的显著标志物。相反，与 NCA 患者相比，miR-328-3p 是 CAAD 的显著标志物。
